Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Inclusion criteria: * Prevalent metformin use + initiation of empagliflozin OR prevalent metformin use + initiation of sulfonylurea * ≥18 years of age at index date during study observation * ≥1 inpatient and/or ≥ 2 outpatient claims denoting T2D diagnosis (in any position) in the 12 months prior to index date * ≥1 inpatient and/or ≥2 outpatient claims denoting CVD (in any position) diagnosis in the 12 months prior to index date * ≥2 months post-index date * ≥12 months of no exposure to T2D medications in the pre-index period (excluding metformin in both arms) * ≥12 months of continuous enrolment prior to index date Exclusion criteria: * Diagnosis of Type 1 Diabetes, secondary, or gestational diabetes in the 12 months prior to index date * Diagnosis of severe comorbidities including malignancy, end-stage renal disease, human immunodeficiency virus, Hepatitis C infection, or organ transplant in the 12 months prior to index date * Admission to nursing home in the 12 months prior to index date